Star Metro - Onco-Innovations Commences Activities to Manufacture Nanoparticle Formulation with Dalton Pharma to Supply Preclinical Animal Studies

NYSE - LSE

CMSC	-0.33%	24.25	$
CMSD	0.12%	24.58	$
SCS	-0.59%	16.88	$
GSK	0.91%	40.67	$
BCC	-2.58%	79.47	$
BTI	-0.4%	54.7	$
JRI	0.65%	13.92	$
NGG	0.14%	70.09	$
BP	-1.29%	34.12	$
RIO	0.64%	62.38	$
RBGPF	0%	76.6	$
RYCEF	-0.13%	15.33	$
AZN	-1.04%	76.28	$
BCE	0.52%	23.22	$
VOD	-0.18%	11.41	$
RELX	-1.23%	47.03	$

Onco-Innovations Commences Activities to Manufacture Nanoparticle Formulation with Dalton Pharma to Supply Preclinical Animal Studies

BOULEVARD 19.09.2025

Onco-Innovations Commences Activities to Manufacture Nanoparticle Formulation with Dalton Pharma to Supply Preclinical Animal Studies

VANCOUVER, BC / ACCESS Newswire / September 19, 2025 / Onco-Innovations Limited (CBOE CA:ONCO )(OTCQB:ONNVF )(Frankfurt:W1H) (WKN: A3EKSZ ) (" Onco " or the " Company ") is pleased to announce that Dalton Pharma Services ("Dalton") has commenced activities to manufacture Onco's proprietary nanoparticle formulation, also know as PEO-b-PBz-CL¹ , a key component of the Company's novel drug delivery platform which is designed for use in conjunction with Onco's proprietary Polynucleotide Kinase Phosphatase (PNKP) inhibitor. The manufacturing initiative is intended to generate the nanoparticle material required to advance preclinical studies.

Text size:

The production campaign will include process optimization and scale-up activities to establish reproducible methods for the synthesis of PEO-b-PBz-CL, while ensuring that the formulation meets quality specifications for purity, molecular weight, and residual solvent levels. Dalton has already demonstrated initial feasibility at the 10 grams scale and will now focus on reducing residual catalyst content and scaling production to 100 grams, followed by a demonstration batch at the 350 grams scale. These activities are designed to provide sufficient quantities of nanoparticle material for formulation development, while also generating the analytical data necessary to support regulatory filings and the eventual transition to Good Manufacturing Practice (GMP) manufacturing.

By engaging Dalton, Onco benefits from the technical expertise and regulatory experience of one of Canada's leading contract development and manufacturing organizations. Dalton's work will provide a comprehensive development package, including full analytical characterization and process documentation, to ensure a smooth path toward clinical readiness of the nanoparticle-formulated platform.

" Advancing the nanoparticle formulation demonstrates will help inform our next phase of development, advancing our pathway toward the clinical opportunities we are determined to reach, " stated Thomas O'Shaughnessy, CEO of Onco-Innovations.

About Onco-Innovations Limited

Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Onco's mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. The company has secured an exclusive worldwide license to patented technology that targets solid tumours.

ON BEHALF OF ONCO-INNOVATIONS LIMITED,

" Thomas O'Shaughnessy "
Chief Executive Officer

For more information, please contact:

Thomas O'Shaughnessy
Chief Executive Officer
Tel: + 1 888 261 8055
[email protected]

Forward-Looking Statements Caution. This news release contains forward-looking statements, including in relation to the benefits expected to be realized under the agreement with Dalton, and the Company's ability to move forward with its plans for manufacturing and further testing and development of its Technologies, the prospects of the Company, and the Company's business and plans generally, and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "potential", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.

¹poly(ethylene oxide)-block-poly(α-benzyl carboxylate ε-caprolactone)

SOURCE: Onco-Innovations Limited

View the original press release on ACCESS Newswire

X.Boucher--SMC

Featured

Google faces court battle over breakup of ad tech business

Google faces a fresh federal court test on Monday as US government lawyers ask a judge to order the breakup of the search engine giant's ad technology business.

Milan Fashion Week to mourn Armani, welcome new stars

Milan Fashion Week opens Tuesday, a feast of Italian style set to be dominated by the late Giorgio Armani's final collections and new faces at Gucci and Versace.

'No amnesty!' Brazilians protest against bid to pardon Bolsonaro

Tens of thousands of Brazilians protested Sunday against "shameless" lawmakers seeking an amnesty that could benefit former president Jair Bolsonaro, while pushing to shield themselves from criminal charges.

Forward Water Technologies Corp. Announces Extension of Non-Brokered Private Placement Closing Date

TORONTO, ON / ACCESS Newswire / September 22, 2025 / Forward Water Technologies Corp. ("FWTC" or the "Company") (TSXV:FWTC) is pleased to announce that, in response to investor interest, it has sought and obtained consent from the TSX Venture Exchange to extend the closing date for its offering of convertible debentures (the "Offering") announced on August 6, 2025. Closing is now expected to occur on or before October 22, 2025. The extended closing time was sought to accommodate a number of recent expressions of interest.